The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration ...

Meena Seshamani believes the landmark Inflation Reduction Act will “lay the foundation” for future drug price negotiations ...

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

RTW forms Prolium to develop Keymed Biosciences' CD20×CD3 bispecific CM355 outside Asia for $17.5M upfront, part of growing ...

Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...